Guideline | Resources |
Bronchiolitis Management in Children: 2014 AAP Guideline | epocrates Guideline Synopsis |
Key Points
Recs apply to immunocompetent children 1 to 23 mo old. RSV is most common cause. Dx is clinical; severity is based on resp rate, retractions, O2 sat, etc. Tx is supportive. Albuterol trial no longer routinely recommended.
Choose Patient Type
|
Clinical Practice Guideline: The Diagnosis, Management, and Prevention of Bronchiolitis. Pediatrics. 2014 Nov;134(5):e1474-502.
Epocrates Guideline Synopsis Last Update:
Oct 1, 2018
Publication Year:
2014
Source:
AAP
- American Academy of Pediatrics
Evidence Grade
[A] | Intervention—well-designed trials, meta-analyses; Diagnosis—independent gold standard studies |
[B] | Trials/diagnostic studies w/ minor limitations; consistent findings from multiple observational studies |
[C] | Single or few observational studies or multiple studies w/ inconsistent findings/major limitations |
[D] | Expert opinion/case reports/reasoning from first principles |
[X] | Exceptional situations where validating studies cannot be performed and there is clear preponderance of benefit or harm |
[S] | Strong recommendation |
[M] | Moderate recommendation |
[W] | Weak recommendation |
Abbreviations
AOM | Acute otitis media |
CXR | Chest x-ray |
NG | Nasogastric |
RSV | Respiratory syncytial virus |
URI | Upper respiratory infection |
Evidence Grade
A | = | Intervention—well-designed trials, meta-analyses; Diagnosis—independent gold standard studies |
B | = | Trials/diagnostic studies w/ minor limitations; consistent findings from multiple observational studies |
C | = | Single or few observational studies or multiple studies w/ inconsistent findings/major limitations |
D | = | Expert opinion/case reports/reasoning from first principles |
X | = | Exceptional situations where validating studies cannot be performed and there is clear preponderance of benefit or harm |
S | = | Strong recommendation |
M | = | Moderate recommendation |
W | = | Weak recommendation |